PCOS Just Got a New Name.
Here's What PMOS Actually Means.
This month, polycystic ovary syndrome was officially renamed. More than 56 clinical and patient organizations reached consensus, with input from over 14,000 people with the condition and multidisciplinary health professionals. The new name is polyendocrine metabolic ovarian syndrome (PMOS). [1]
The old name was always wrong in a specific way. Despite the name, many patients do not have ovarian cysts, and the terminology contributed to missed diagnoses and inadequate treatment for decades. The "cysts" seen on ultrasound are arrested follicles, not pathological cysts. Research showed this terminology led to diagnostic delays affecting up to 70% of those with the condition, and fragmented care. [2] [3]
The name sent treatment in the wrong direction for decades. Birth control to regulate the cycle. Progesterone support. Ovulation monitoring. For some women, this helped. For a lot of women, it managed the downstream effects while the actual driver went untouched.
The new name says what the research has been pointing toward. "Polyendocrine" recognizes that multiple interacting hormonal disturbances are involved, including insulin, androgens, and neuroendocrine hormones, rather than an isolated ovarian disorder. "Metabolic" acknowledges inherent features like insulin resistance, obesity risk, and increased risk for type 2 diabetes and cardiovascular disease. "Ovarian" keeps the ovaries in the picture as a downstream consequence, not the cause. [3]
Research suggests that up to 70% of women with the condition experience some degree of insulin resistance, regardless of body weight. Most don't know it because standard bloodwork checks fasting glucose, not insulin sensitivity. Normal glucose doesn't rule out insulin resistance. [4]
This is the gap that explains why so many women are told their labs are normal while still experiencing the full pattern: the fatigue that hits at specific points in the month, the skin changes, the cycle irregularity, the weight that doesn't respond to what should work.
If your PCOS management focused mainly on reproductive outcomes, the metabolic component may never have been treated. Not because your doctor was wrong, but because the framework it was diagnosed under didn't ask the right questions.
The name change also opens the door for women who suspected something hormonal was wrong but never fit a clean PCOS diagnosis. The new name recognizes a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological, and psychological health. The metabolic framing is broader. It covers more of what's actually happening. [4]
I'm writing more about this: what the updated research points to for supplement choices and daily routine, and what I'm personally trying. Subscribe below to stay updated.
References:
- Teede HJ, et al. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet, May 12, 2026. https://doi.org/10.1016/S0140-6736(26)00717-8
- Cree, Melanie. "Global Experts, Including CU Anschutz Researcher, Rename Polycystic Ovary Syndrome (PCOS)." University of Colorado Anschutz Medical Campus News, May 2026. https://news.cuanschutz.edu/news-stories/pcos-new-name
- "Global consensus renames PCOS to polyendocrine metabolic ovarian syndrome (PMOS)." Contemporary OB/GYN, May 2026. https://www.contemporaryobgyn.net/view/global-consensus-renames-pcos-to-polyendocrine-metabolic-ovarian-syndrome-pmos-
- Essah, Paulina A., and John E. Nestler. "Insulin Resistance and Hyperinsulinism in the Polycystic Ovary Syndrome." In Azziz, R., Nestler, J.E., Dewailly, D. (eds.), Androgen Excess Disorders in Women, Contemporary Endocrinology. Humana Press, 2006, pp. 273–281. https://doi.org/10.1007/978-1-59745-179-6_24
